Snyder, Robert W., M.D., Ph.D., P.C. Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03022318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Robert Snyder, MD, PhD, PC | Snyder, Robert W., M.D., Ph.D., P.C.

Active Ingredients

Drugs in Phase 2 Trials (2)

carbidopa (sinemet) (5 trials)

levodopa (larodopa) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2